BTAIQOTCPharmaceutical PreparationsFiscal year ends December 31
BioXcel Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.03−0.00 (-13.49%)
Close on Oct 19, 2026
- Market cap
- $757.50K
- P/E (TTM)
- –
- Dividend yield
- –
BioXcel Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | BioXcel Therapeutics | Industry median |
|---|---|---|
| Market Cap | $782.64K | $166.30M |
| Enterprise Value | $92.39M | $88.19M |
| PS Ratio | 1.05 | 3.65 |
Enterprise value
| Measure | BioXcel Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 124.52 | 2.51 |
Income (trailing twelve months)
| Measure | BioXcel Therapeutics | Industry median |
|---|---|---|
| Revenue | $742.00K | $58.34M |
| Gross Profit | $394.00K | $105.94M |
| Operating Income | -$44.93M | -$21.40M |
| Net Income | -$70.86M | -$22.46M |
| EBITDA | -$44.93M | -$16.91M |
| EPS (Diluted) | -$3.78 | -$0.83 |
Margins
| Measure | BioXcel Therapeutics | Industry median |
|---|---|---|
| Gross Margin | 53.1% | 52.9% |
| Operating Margin | -6054.7% | -44.0% |
| Profit Margin | -9549.9% | -40.2% |
| EBITDA Margin | -6054.7% | -30.2% |
| FCF Margin | -6860.4% | -9.27% |
Returns
| Measure | BioXcel Therapeutics | Industry median |
|---|---|---|
| Return on Assets (ROA) | -259.6% | -40.9% |
Growth
| Measure | BioXcel Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -14.5% | 5.96% |
| Revenue Growth (3Y CAGR) | 19.6% | 2.25% |
Balance sheet
| Measure | BioXcel Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $12.84M | $61.43M |
| Total Debt | $104.45M | $118.52M |
| Net Cash (Debt) | -$91.61M | $15.35M |
| Net Cash Per Share | -$2.93 | $0.66 |
| Equity (Book Value) | -$115.46M | $49.09M |
| Book Value Per Share | -$3.69 | $1.37 |
| Tangible Book Value | -$115.46M | $23.52M |
| Working Capital | -$108.45M | $76.81M |
Financial position
| Measure | BioXcel Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 0.21 | 3.34 |
| Quick Ratio | 0.09 | 2.44 |
| Interest Coverage | -2.61 | -6.26 |
Cash flow (trailing twelve months)
| Measure | BioXcel Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$50.90M | -$12.35M |
| Capital Expenditures | $0 | -$1.08M |
| Free Cash Flow | -$50.90M | -$20.22M |
| FCF Per Share | -$1.63 | -$0.42 |
Efficiency
| Measure | BioXcel Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.03 | 0.39 |
| Inventory Turnover | 0.70 | 2.70 |
| Revenue Per Employee | $20.05K | $404.87K |
| Profits Per Employee | -$1.92M | -$703.34K |
| Employee Count | 37 | 74 |
Dividends and yields
| Measure | BioXcel Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -9054.0% | -23.3% |
| FCF Yield | -6504.2% | -8.72% |
Shares
| Measure | BioXcel Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 31,305,500 | 58,127,000 |
| Shares Change (YoY) | 389.6% | 10.9% |
| Shares Change (QoQ) | 15.6% | 0.54% |
| Float | 30,355,700 | 49,136,700 |
| Shares Held by Insiders | 3.03% | 11.6% |
| Shares Held by Institutions | 19.7% | 59.4% |
Scores
| Measure | BioXcel Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -45.98 | -0.22 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from BioXcel Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.